×
About 4,563 results

ALLMedicine™ Dermatomyositis Center

Research & Reviews  1,522 results

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Li...
https://doi.org/10.1007/s11606-021-07131-7 10.1097/MD.0b013e3182606f0b 10.1016/j.amjmed.2018.09.013 10.5387/fms.2018-01 10.1016/j.rdc.2019.07.006 10.1097/BOR.0b013e32833f1970 10.1016/s1474-4422(18)30254-0
Journal of General Internal Medicine; Kersey CB, Oshinsky C et. al.

Sep 26th, 2021 - Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review.|2021|Kersey CB,Oshinsky C,Wahl ER,Newman TA,|

A Narrative Review of Therapies for Scalp Dermatomyositis.
https://doi.org/10.1111/dth.15138
Dermatologic Therapy; Avani M Kolla B, Liu L et. al.

Sep 23rd, 2021 - Cutaneous involvement of the scalp is a common manifestation of dermatomyositis (DM), occurring in up to 82% percent of adults with DM. Scalp DM predominantly affects women and is characterized by dermatitis, alopecia, pruritus, and/or burning. Wh...

Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study.
https://doi.org/10.1002/acr.24786
Arthritis Care & Research; Kronzer VL, Kimbrough BA et. al.

Sep 23rd, 2021 - We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria. This population-based cohort ...

Nomogram to predict dermatomyositis prognosis: a population-based study of 457 cases.
https://www.ncbi.nlm.nih.gov/pubmed/34528507
Clinical and Experimental Rheumatology; Li Y, Li Y et. al.

Sep 17th, 2021 - Dermatomyositis (DM) is a systemic autoimmune disease, which typically affects the striated muscle with a variable involvement of the skin and other organs. Clinically amyopathic DM (CADM) is a combination of hypomyopathic DM (HDM) and amyopathic ...

Consumer-based activity trackers in evaluation of physical activity in myositis patients.
https://doi.org/10.1093/rheumatology/keab700
Rheumatology (Oxford, England); Saygin D, Rockette-Wagner B et. al.

Sep 17th, 2021 - Inflammatory myopathies are characterized by muscle weakness that limit activities of daily living. Daily step count is an accepted metric of physical activity. Wearable technologies such as Fitbit® enable tracking of daily step counts. We assesse...

see more →

Guidelines  3 results

Treatment consensus for management of polymyositis and dermatomyositis among rheumatolo...
https://doi.org/10.1111/1346-8138.14604
The Journal of Dermatology; Kohsaka H, Mimori T et. al.

Dec 19th, 2018 - Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the trea...

2016 American College of Rheumatology/European League Against Rheumatism criteria for m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496443
Annals of the Rheumatic Diseases; Aggarwal R, Rider LG et. al.

Apr 8th, 2017 - To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement ...

2016 American College of Rheumatology/European League Against Rheumatism Criteria for M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517365
Annals of the Rheumatic Diseases; Rider LG, Aggarwal R et. al.

Apr 8th, 2017 - To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheum...

see more →

Drugs  170 results see all →

News  129 results

FDA Approves Intravenous Immunoglobulin for Dermatomyositis
https://www.medscape.com/viewarticle/955142

Jul 21st, 2021 - The Food and Drug Administration has approved Octagam 10% as the first intravenous immunoglobulin with an indication specifically for adult dermatomyositis, according to a statement from manufacturer Octapharma USA. Dermatomyositis is a rare, idio...

Polymyositis-Dermatomyositis Tied to Arrhythmias in Young, Middle-Aged Adults
https://www.medscape.com/viewarticle/953329

Jun 18th, 2021 - (Reuters Health) - Young and middle-aged adults with polymyositis-dermatomyositis are more likely to have arrhythmias in general, and supraventricular arrhythmias in particular, than matched controls without these rare rheumatic conditions, a U.S....

Intravenous Immunoglobulin Controls Dermatomyositis in Phase 3 Trial
https://www.medscape.com/viewarticle/952385

Jun 3rd, 2021 - The first multinational, phase 3, placebo-controlled trial conducted with intravenous immunoglobulin therapy (IVIg) for dermatomyositis has confirmed significant efficacy and acceptable safety, according to data presented at the opening plenary ab...

The Use of Autoantibody Testing in a Postpartum Patient at Risk for Malignancy-Associated Dermatomyositis
https://www.medscape.com/viewarticle/950202

May 4th, 2021 - This article originally appeared on the Hospital for Special Surgery website. Case Report In May 2019, a 32-year-old woman developed a rash on her face, chest, and knuckles, initially thought to be contact dermatitis. She saw a second dermatologis...

Consider Home Subcutaneous Immune Globulin for Refractory Dermatomyositis
https://www.medscape.com/viewarticle/946138

Feb 19th, 2021 - Home-based subcutaneous immune globulin therapy is a promising alternative to intravenous immune globulin therapy for patients with refractory dermatomyositis or polymyositis, Anna Postolova, MD, MPH, declared at the 2021 Rheumatology Winter Clini...

see more →

Patient Education  1 results see all →